報價延遲最少15分鐘:2025/09/16 21:50 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.37 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.86/-0.55
|
|
企業價值
13.46M
|
| 資產負債 |
|
每股賬面淨值
0.05
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
1.63M
|
|
每股收益
0.04
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/09/16 21:50 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets. |
